PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novozymes Biopharma to Present Latest Research on Recombinant Human Albumin At AAPS - Recombinant human albumin as a multifunctional excipient for the stabilisation of therapeutic protein formulations. Study results to be presented at the 2011 AAPS National Biotechnology Conference
Novozymes Biopharma to Present Latest Research on Recombinant Human Albumin At AAPS

 

NewswireToday - /newswire/ - Nottingham, United Kingdom, 2011/03/22 - Recombinant human albumin as a multifunctional excipient for the stabilisation of therapeutic protein formulations. Study results to be presented at the 2011 AAPS National Biotechnology Conference.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced a new scientific poster on recombinant human albumin to be presented at the 2011 AAPS National Biotechnology Conference, May 16-18, San Francisco, California. The poster reveals the results of the company's latest study on the use of recombinant human albumin for the stabilization of therapeutic proteins. For more information or to request a copy of the scientific poster, please visit table #32 at the 2011 AAPS National Biotechnology Conference.

The therapeutic and ultimately the commercial success of a protein-based drug depends upon the ability to produce a formulation with an adequate stability profile. The mechanisms of protein instability are complex and typically multiple excipients are required to address factors such as aggregation, oxidation and nonspecific adsorption during protein formulation.

"We are proud to present our latest, breakthrough research on recombinant human albumin and share our invaluable knowledge with other industry experts", comments Dermot Pearson, marketing director at Novozymes Biopharma. "As a leader in biomanufacturing and process development, we continue to perform studies designed to demonstrate how animal-free rAlbumin can help the industry optimize drug formulation, development and delivery."

The new poster, entitled "Recombinant Human Albumin: A Multifunctional Excipient for the Stabilisation of Therapeutic Protein Formulations", demonstrates the potential for recombinant human albumin (rAlbumin) to act as a multifunctional stabilisation excipient for protein and peptide formulations. The poster describes the study undertaken to investigate the stability of the rAlbumin with respect to pH and temperature to assess the suitability of this molecule for incorporation into protein formulations.

The study results indicate that rAlbumin is a multifunctional excipient, protecting protein-based active ingredients against aggregation, oxidation and non-specific binding in solution. The multifunctional nature of rAlbumin may lead to opportunities to explore simpler protein formulations with reduced numbers of excipients. Additionally, the stability of the molecule reveals its potential to be used under a wide range of formulation conditions.

For further information on Novozymes products or to request a copy of the new scientific poster, please visit table #32 at the 2011 AAPS National Biotechnology Conference.

About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.

Contact:
Novozymes Biopharma:
Sally Vernon, Customer Communications Manager SYKE[.]novozymes.com T: +44 115 955 3355

MEDIA CONTACTS

Europe - René Tronborg
Office: +45 4446 2274 / Mobile: +45 3077 2274 - retr[.]novozymes.com.

US - Paige Donnelly
Office: +1 919 494 3209 / Mobile: +1 919 218 4501 - pagd[.]novozymes.com.

China - Zhu Xiaoqing
Office: +86 106 298 7888+362 / Mobile: +86 138 012 40590 - xqzh[.]novozymes.com.

Brazil - Saionara Ribeiro de Paula
Office: +55 41 3641 1112 / Mobile: +55 41 9971 7225 - saio[.]novozymes.com.

INVESTOR CONTACTS

Europe - Tobias Bjorklund
Office: +45 4446 8682 / Mobile: +45 3077 8682 - tobb[.]novozymes.com.

US - Thomas Steenbech Bomhoff
Mobile: +1 919 649 2565 / tsbm[.]novozymes.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Novozymes Biopharma to Present Latest Research on Recombinant Human Albumin At AAPS

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Scottpr.com 
+44 1477 539539
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Traditional Mass Spectrometers Give Way to High-resolution Technologies Such as MALDI-TOF Finds Frost & Sullivan
AccuVein, Inc. Named A Best Place to Work in Medical Sales for Second Consecutive Year
MRI Inventor to Receive the Medtech Innovation Catalyst Award
Ansell Limited Acquires Cleanroom and Healthcare Consumables Manufacturer Nitritex Limited
ZOLL to Showcase Expanded Portfolio of Advanced Resuscitation and Acute Critical Care Technologies at Arab Health 2017
Frost & Sullivan Awards Ansell for Entrenching itself in the Hand Protection Market with its Visionary Products and Technologies
ZOLL RescueNet ePCR Achieves Latest National Compliance Standard
Eye Tech Care Wins Top Honours from Frost & Sullivan for Developing the EyeOP1, the Only Computer-assisted System for Glaucoma Therapy
Frost & Sullivan Recognizes Nuvectra’s Pioneering Spinal Cord Stimulation Product for Chronic Pain Management
GE Healthcare to Commercialize Rapiscan® Outside the US, Canada & Mexico for Increased Access to Heart Exams
Novel Home Care Needs and Customer Preferences Catalyse Growth Opportunities in Mature Cardiac Monitoring Market Finds Frost & Sullivan
Frost & Sullivan Highlights Inspirata's Leading-edge Digital Pathology Solutions that Accelerate Cancer Diagnostics, Monitoring, Treatment
Sparta Systems Broadens Partnership with TrackWise Implementation Specialist Equality Systems
Thales Launches the Pixium Portable 3543 DR Wifi Enabled Flat Panel Detector
GE Healthcare Showcases Industry-first Technologies and Digital Solutions, Focused on Improving Outcomes, At RSNA 2016

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)